rs121918393 — APOE Christchurch (R136S)

The Christchurch Mutation — Nature's Blueprint for Alzheimer's Resistance

Apolipoprotein E (ApoE) is the most powerful common genetic determinant of Alzheimer's disease risk in the human genome. The APOE4 allele increases lifetime risk 3–4 fold in heterozygotes and 8–12 fold in homozygotes; APOE2 is modestly protective. But in 2019, a third piece of the puzzle emerged: an ultra-rare variant called APOE3 Christchurch (R136S), carried in homozygous form by a single Colombian woman, appeared to nearly abolish Alzheimer's disease pathology despite her carrying the most penetrant familial AD mutation known — PSEN1 E280A, which causes dementia in virtually all carriers by their late 40s.

Arboleda-Velasquez et al. 2019¹¹ Arboleda-Velasquez et al. 2019
Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine reported that this woman did not develop mild cognitive impairment until her 70s — nearly 30 years after the expected onset of ~44 years in her 1,200-member kindred. Brain imaging revealed unusually high amyloid burden but remarkably limited tau pathology and preserved metabolism in AD-vulnerable regions. The implication: the Christchurch mutation somehow broke the link between amyloid accumulation and downstream tau-driven neurodegeneration.

The Mechanism

The R136S substitution — arginine to serine at position 136 of the mature protein (154 in the pre-protein, hence the dual nomenclature R136S / p.Arg154Ser) — falls squarely within the heparan sulfate proteoglycan (HSPG) binding domain²² heparan sulfate proteoglycan (HSPG) binding domain
HSPGs are abundant cell-surface and extracellular matrix proteins that act as co-receptors for ApoE. The Christchurch substitution dramatically weakens HSPG affinity.

This matters because HSPG binding drives several of ApoE's most damaging effects in the AD brain. Wang et al. 2023 (Nature Neuroscience)³³ Wang et al. 2023 (Nature Neuroscience) showed that the homozygous R136S mutation rescued APOE4-driven phosphorylated tau accumulation, neuroinflammation, and neurodegeneration in both mouse tauopathy models and human iPSC-derived neurons. Single-nucleus RNA sequencing demonstrated that R136S increased disease-protective and reduced disease-associated cell populations in a gene-dose-dependent manner — homozygotes showed full rescue, heterozygotes partial.

Two additional mechanisms have since been characterized. Zhang et al. 2024 (Neuron)⁴⁴ Zhang et al. 2024 (Neuron) found that the R136S mutant protein directly binds tau with higher affinity than wild-type ApoE3, blocking tau uptake into neurons and microglia and reducing tau fragmentation by the asparagine endopeptidase AEP — a key step in tau propagation. Separately, Wang et al. 2024 (Immunity)⁵⁵ Wang et al. 2024 (Immunity) demonstrated that R136S inhibits the cGAS-STING interferon pathway, suppressing the chronic neuroinflammatory signaling that amplifies tau pathology.

On the lipid side, the same HSPG/LDL-receptor-related protein binding domain affected by R136S is required for efficient clearance of triglyceride-rich remnant lipoproteins. This means heterozygotes and homozygotes for the Christchurch allele can develop type III hyperlipoproteinemia⁶⁶ type III hyperlipoproteinemia
a.k.a. dysbetalipoproteinemia; impaired clearance of IDL and VLDL remnants causing elevated total cholesterol and triglycerides, particularly when combined with other dyslipidemia-predisposing factors.

The Evidence

The founding 2019 case report was remarkable but N=1. Subsequent research has substantially broadened the evidence base.

Saez-Calveras et al. 2023 (Mol Neurodegeneration)⁷⁷ Saez-Calveras et al. 2023 (Mol Neurodegeneration) analyzed 455,306 UK Biobank participants and identified 37 heterozygous APOEch carriers (36 European, 1 admixed American; median age 68.6 years). None had developed AD or MCI by the data freeze. Carriers showed lower apolipoprotein B levels and a significantly reduced polygenic risk score for AD (p=0.02). The allele frequency in UK Biobank was approximately 0.004%.

Lopera et al. 2024 (NEJM)⁸⁸ Lopera et al. 2024 (NEJM) quantified the heterozygous effect in the Colombian PSEN1 E280A kindred: among 27 heterozygous APOEch carriers, median MCI onset was 52 years versus 47 years in matched non-carriers — a 5-year delay, statistically significant (p<0.001). Two heterozygous carriers who underwent brain imaging showed relatively preserved FDG-PET metabolic activity in AD-vulnerable regions. Four autopsy specimens from APOEch carriers showed fewer vascular amyloid deposits. The protective effect is real in heterozygotes, but substantially more modest than in the original homozygous case.

The overall allele frequency is approximately 1–4 per 100,000 in European populations and even rarer in other ancestries. The probability of inheriting two copies (homozygous, as in the Colombian case) is therefore roughly 1 in 600 million to 1 in 6 billion — making the original case effectively unique in human clinical history.

Practical Actions

For the overwhelming majority of people tested, this SNP will return the wild-type CC genotype — the Christchurch allele is too rare to appear in most population samples. The primary clinical relevance is for individuals who carry the AC genotype (heterozygous):

The 5-year delay in PSEN1 E280A carriers is meaningful and suggests that even a single copy of the Christchurch allele provides real neurological protection, likely through partial reduction in HSPG binding and partial tau propagation block. Heterozygous carriers should monitor lipid panels carefully, as the same HSPG/LDL-receptor binding impairment that protects the brain can impair remnant lipoprotein clearance. This is not a reason to treat aggressively, but it is a reason to track.

The Christchurch mutation is now the leading molecular template for next-generation Alzheimer's drug development. Mimetic antibodies that block the HSPG-binding domain of wild-type ApoE are in preclinical development, and the variant itself is being explored for AAV gene delivery as a therapeutic.

Interactions

The Christchurch mutation's protection is most dramatic on an APOE3 backbone (the original Colombian case was APOE3/APOE3-ch). Subsequent work has shown R136S is also protective on an APOE4 background — Wang et al. 2023⁹⁹ Wang et al. 2023 demonstrated R136S on APOE4 rescued most tau and neuroinflammation endpoints in model systems, though with somewhat attenuated effect compared to APOE3 background.

The two canonical APOE isoform SNPs — rs429358¹⁰¹⁰ rs429358 (the ε4-defining Cys112Arg) and rs7412¹¹¹¹ rs7412 (the ε2-defining Arg158Cys) — both fall in the LDL receptor binding region of ApoE and influence AD risk through overlapping but distinct mechanisms. The Christchurch mutation falls in the HSPG-binding subdomain adjacent to the LDL receptor binding site, and its protection is at least partially independent of APOE isoform, as shown by the iPSC data generating APOE2ch, APOE3ch, and APOE4ch constructs.

For individuals with a family history of early-onset Alzheimer's disease, both rs75932628¹²¹² rs75932628 (TREM2 R47H) and rs3851179¹³¹³ rs3851179 (PICALM) influence microglial clearance of amyloid and tau — the same downstream pathways Christchurch modulates — and would be relevant to examine in conjunction.